Asfrenon Warnings

Special risk patients: Administer with caution to individuals with unstable vasomotor systems, diabetes, hyperthyroidism, prostatic hypertrophy and history of seizures. Also administer with caution to elderly patients, psychoneurotic individuals and patients with long-standing bronchial asthma and emphysema who have developed degenerative heart disease.
Local Irritation: Powder formulation may irritate the oropharynx and tracheobronchial tree, consider use secondary to solutions or suspensions. Reduce dosage if bronchial irritation, nervousness, restlessness occur. In patients with status asthmaticus and abnormal blood gas, tensions may not accompany apparent relief of bronchospasm.
Facilities for administering oxygen and ventilatory assistance are necessary.
Cardiovascular Effects: Use with caution in patients with cardiovascular disorders including coronary insufficiency, a history of stroke, coronary artery disease, cardiac arrhythmias and hypotension. This agent may cause toxic symptoms through idiosyncratic response or overdose. Patients with atrial fibrillation show an exaggerated increase in heart rate response. If the cardiac rate increases sharply, patients with angina pectoris may increase anginal pain until the cardiac rate decreases. Closely monitor patients receiving epinephrine advertently include high arterial blood pressure may result in angina pectoris, aortic rupture or cerebral hemorrhage. Cardiac arrhythmias develop in some individuals even after therapeutic doses. Epinephrine causes changes in the ECG even in normal persons, including a decrease in amplitude of the T wave. Administer with great care to patients with cardiac arrhythmias, coronary insufficiency, ischemic heart disease, coronary artery or organic heart disease and hypertension.